NCT06146478View on ClinicalTrials.gov

Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

July 20, 2023

Study Completion Date

October 31, 2023

Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
DRUG

Thalidomide

Thalidomide given at an average dose of 1.5mg/kg/day

Trial Locations (1)

Unknown

Blood Care Clinic, Peshawar

All Listed Sponsors
collaborator

Khyber Medical University Peshawar

OTHER

lead

Blood Care Clinic

OTHER